Limited-sampling models for anticancer agents
Authors:
- 1 July 1994
- journal article
- review article
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 120 (7) , 427-433
Abstract
Pharmacokinetic parameters of antineoplastic drugs are usually generated from concentration/time profiles obtained after multiple venipunctures. With limited-sampling models (LSM) this number can be reduced to between one and three timed plasma samples. LSMs may facilitate population pharmacokinetic/pharmacodynamic studies, which eventually may lead to a dosing strategy based on the characteristics of the individual patient. In this article, the development, validation and application of several LSMs reported in the literature are reviewed.Keywords
This publication has 57 references indexed in Scilit:
- Bayesian Parameter Estimation and Population PharmacokineticsClinical Pharmacokinetics, 1992
- Pharmacokinetic Optimisation of Anticancer TherapyClinical Pharmacokinetics, 1991
- Pharmacokinetics of 5-Fluorouracil After Short Systemic InfusionTherapeutic Drug Monitoring, 1991
- Clinical Pharmacokinetics-Pharmacodynamicsof Anticancer DrugsClinical Pharmacokinetics, 1989
- Therapeutic Drug Monitoring in OncologyClinical Pharmacokinetics, 1987
- Pharmacokinetically guided dose escalation in phase I clinical trials. Commentary and proposed guidelinesEuropean Journal of Cancer and Clinical Oncology, 1987
- Some suggestions for measuring predictive performanceJournal of Pharmacokinetics and Biopharmaceutics, 1981
- Hypothesis for the Individualisation of Drug DosageClinical Pharmacokinetics, 1979
- Clinical Pharmacokinetics of CyclophosphamideClinical Pharmacokinetics, 1979
- Use of Plasma Pharmacokinetics to Predict and Prevent Methotrexate ToxicityNew England Journal of Medicine, 1977